|
1
|
Machens A, Brauckhoff M, Holzhausen HJ,
Thanh PN, Lehnert H and Dralle H: Codon-specific development of
pheochromocytoma in multiple endocrine neoplasia type 2. J Clin
Endocrinol Metab. 90:3999–4003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wells SA Jr, Pacini F, Robinson BG and
Santoro M: Multiple endocrine neoplasia type 2 and familial
medullary thyroid carcinoma: An update. J Clin Endocrinol Metab.
98:3149–3164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kouvaraki MA, Shapiro SE, Perrier ND, Cote
GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE and Evans DB: RET
proto-oncogene: A review and update of genotype-phenotype
correlations in hereditary medullary thyroid cancer and associated
endocrine tumors. Thyroid. 15:531–544. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brandi ML, Gagel RF, Angeli A, Bilezikian
JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG,
Libroia A, et al: Guidelines for diagnosis and therapy of MEN type
1 and type 2. J Clin Endocrinol Metab. 86:5658–5671. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trimboli P, Giovanella L, Crescenzi A,
Romanelli F, Valabrega S, Spriano G, Cremonini N, Guglielmi R and
Papini E: Medullary thyroid cancer diagnosis: An appraisal. Head
Neck. 36:1216–1223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Thyroid Association Guidelines
Task Force, . Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF,
Gharib H, Moley JF, Pacini F, Ringel MD, et al: Medullary thyroid
cancer: Management guidelines of the American Thyroid Association.
Thyroid. 19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu MI, Ying AK and Jimenez C: Update on
medullary thyroid cancer. Endocrinol Metab Clin North Am.
43:423–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toledo RA, Wagner SM, Coutinho FL,
Lourenco DM Jr, Azevedo JA, Longuini VC, Reis MT, Siqueira SA,
Lucon AM, Tavares MR, et al: High penetrance of pheochromocytoma
associated with the novel C634Y/Y791F double germline mutation in
the RET protooncogene. J Clin Endocrinol Metab. 95:1318–1327. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cranston AN, Carniti C, Oakhill K,
Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S,
Mondellini P, Leyland J, et al: RET is constitutively activated by
novel tandem mutations that alter the active site resulting in
multiple endocrine neoplasia type 2B. Cancer Res. 66:10179–10187.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwashita T, Murakami H, Kurokawa K, Kawai
K, Miyauchi A, Futami H, Qiao S, Ichihara M and Takahashi M: A
two-hit model for development of multiple endocrine neoplasia type
2B by RET mutations. Biochem Biophys Res Commun. 268:804–808. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barbieri RB, Bufalo NE, Secolin R, Silva
AC, Assumpção LV, Maciel RM, Cerutti JM and Ward LS: Evidence that
polymorphisms in detoxification genes modulate the susceptibility
for sporadic medullary thyroid carcinoma. Eur J Endocrinol.
166:241–245. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai T, Uchino S, Okamoto T, Suzuki S,
Kosugi S, Kikumori T and Sakurai A: MEN Consortium of Japan: High
penetrance of pheochromocytoma in multiple endocrine neoplasia 2
caused by germ line RET codon 634 mutation in Japanese patients.
Eur J Endocrinol. 168:683–687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sippel RS, Kunnimalaiyaan M and Chen H:
Current management of medullary thyroid cancer. Oncologist.
13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dionigi G, Bianchi V, Rovera F, Boni L,
Piantanida E, Tanda ML, Dionigi R and Bartalena L: Medullary
thyroid carcinoma: Surgical treatment advances. Expert Rev
Anticancer Ther. 7:877–885. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Enewold L, Zhu K, Ron E, Marrogi AJ,
Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer
incidence in the United States by demographic and tumor
characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev.
18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kebebew E, Ituarte PH, Siperstein AE, Duh
QY and Clark OH: Medullary thyroid carcinoma: Clinical
characteristics, treatment, prognostic factors, and a comparison of
staging systems. Cancer. 88:1139–1148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machens A, Ukkat J, Hauptmann S and Dralle
H: Abnormal carcinoembryonic antigen levels and medullary thyroid
cancer progression: A multivariate analysis. Arch Surg.
142:289–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Z, Qi X, Fei J, Yu X, Zhao Y, Zhao J,
Jin H, Wang J, Ying R and Zhang X: Multiple endocrine neoplasia
type 2A caused by a p.C618R RET proto-oncogene mutation in a
Chinese pedigree. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 31:348–351.
2014.(In Chinese). PubMed/NCBI
|
|
19
|
Schreinemakers JM, Vriens MR, Valk GD, de
Groot JW, Plukker JT, Bax K, Hamming JF, van der Luijt RB, Aronson
DC and Borel Rinkes IH: Factors predicting outcome of total
thyroidectomy in young patients with multiple endocrine neoplasia
type 2: A nationwide long-term follow-up study. World J Surg.
34:852–860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niederle B, Sebag F and Brauckhoff M:
Timing and extent of thyroid surgery for gene carriers of
hereditary C cell disease-a consensus statement of the European
society of endocrine surgeons (ESES). Langenbecks Arch Surg.
399:185–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Machens A, Ukkat J, Brauckhoff M, Gimm O
and Dralle H: Advances in the management of hereditary medullary
thyroid cancer. J Intern Med. 257:50–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaserer K, Scheuba C, Neuhold N,
Weinhäusel A, Vierhapper H and Niederle B: Recommendations for
reporting C cell pathology of the thyroid. Wien Klin Wochenschr.
114:274–278. 2002.PubMed/NCBI
|
|
23
|
Kaserer K, Scheuba C, Neuhold N,
Weinhäusel A, Haas OA, Vierhapper H and Niederle B: Sporadic versus
familial medullary thyroid microcarcinoma: A histopathologic study
of 50 consecutive patients. Am J Surg Pathol. 25:1245–1251. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wolfe HJ, Melvin KE, Cervi-Skinner SJ,
Saadi AA, Juliar JF, Jackson CE and Tashjian AH Jr: C-cell
hyperplasia preceding medullary thyroid carcinoma. N Engl J Med.
289:437–441. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kurzrock R, Atkins J, Wheler J, Fu S,
Naing A, Busaidy N, Hong D and Sherman S: Tumor marker and
measurement fluctuations may not reflect treatment efficacy in
patients with medullary thyroid carcinoma on long-term RET
inhibitor therapy. Ann Oncol. 24:2256–2261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shively JE and Beatty JD: CEA-related
antigens: Molecular biology and clinical significance. Crit Rev
Oncol Hematol. 2:355–399. 1985. View Article : Google Scholar : PubMed/NCBI
|
